Abstract
Introduction: Using nanoparticle (NP) drugs can have better effects on the target tissue in various diseases. Alzheimer’s disease (AD) is one of the degenerative neurological diseases that due to its high prevalence, requires the use of more appropriate treatments. Therefore, the aim of this study was consideration of the effect of cannabidiol (CBD) coated by nano-chitosan on learning and memory, hippocampal cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 1 (CB2) levels, and amyloid plaques in an AD rat model. Material and Methods: Thirty-five male Wistar rats were randomly divided into 5 groups (n = 7 in each): control, Alzheimer’s disease model that received the beta-amyloid (Aβ) peptide (Alz), Alz + nano-chitosan (NP) Alz + CBD, and Alz + NP + CBD. Alz was induced by injection of the Aβ1-42 peptide into the hippocampal area cornu ammonis1. After confirmation of Alz, 1 μL of CBD and NP + CBD were administered by oral gavage daily in rats for 1 month. The Morris water maze (MWM) test was used to assess learning and memory of animals. Cresyl violet staining was used for consideration of dead cells. Gene and protein expression of CB1 and CB2 was performed by real-time PCR and immunohistochemistry methods. Results: Induction of Alz significantly increased Aβ plaques and dead cells compared to the control group (p < 0.001). Results of MWM in the day test show that Alz + NP + CBD significantly decrease escape latency (p < 0.01), travelled distance (p < 0.001), and significantly increased spending time (p < 0.001) compared to the Alz group. Protein expression of CB1 and CB2 significantly increased in Alz + CBD and Alz + NP + CBD compared to the Alz group (p < 0.05). Conclusion: It seems that CBD coated by nano-chitosan has good potential for reducing Aβ plaques, increasing brain CB1 and levels CB2, and improving learning and memory in Alz rats.
References
1.
van de Weijer
MP
, Jansen
IE
, Verboven
AHA
, Andreassen
OA
, Posthuma
D
. Genomics of alzheimerʼs disease
. Personalized Psychiatry
. 2020
;22
:275
–83
. .2.
Sweeney
P
, Park
H
, Baumann
M
, Dunlop
J
, Frydman
J
, Kopito
R
, Protein misfolding in neurodegenerative diseases: implications and strategies
. Transl Neurodegener
. 2017
;6
(1
):6
. .3.
Lim
KH
. Diverse misfolded conformational strains and cross-seeding of misfolded proteins implicated in neurodegenerative diseases
. Front Mol Neurosci
. 2019
;12
:158
. .4.
Gottesman
RT
, Stern
Y
. Behavioral and psychiatric symptoms of dementia and rate of decline in alzheimerʼs disease
. Front Pharmacol
. 2019
;10
:1062
. .5.
Sadigh-Eteghad
S
, Sabermarouf
B
, Majdi
A
, Talebi
M
, Farhoudi
M
, Mahmoudi
J
. Amyloid-beta: a crucial factor in alzheimerʼs disease
. Med Princ Pract
. 2015
;24
(1
):1
–10
. .6.
Calderon-Garcidueñas
AL
, Duyckaerts
C
. Alzheimer disease
. Handb Clin Neurol Elsevier
. 2018
;145
:325
–37
. .7.
Komura
H
, Kakio
S
, Sasahara
T
, Arai
Y
, Takino
N
, Sato
M
, Alzheimer Aβ assemblies accumulate in excitatory neurons upon proteasome inhibition and kill nearby NAKα3 neurons by secretion
. iScience
. 2019
;13
:452
–77
. .8.
Jash
K
, Gondaliya
P
, Kirave
P
, Kulkarni
B
, Sunkaria
A
, Kalia
K
. Cognitive dysfunction: a growing link between diabetes and alzheimerʼs disease
. Drug Develop Res
. 2020
;81
(2
):144
–64
.9.
Benfeito
S
, Fernandes
C
, Vilar
S
, Remião
F
, Uriarte
E
, Borges
F
. Exploring the multi-target performance of mitochondriotropic antioxidants against the pivotal alzheimerʼs disease pathophysiological hallmarks
. Molecules
. 2020
;25
(2
):276
. .10.
Hao
F
, Feng
Y
. Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimerʼs mice uncovered by RNA-seq
. Life Sci
. 2021
;264
:118624
. .11.
Veldhuis
WB
, Van der Stelt
M
, Wadman
MW
, Van Zadelhoff
G
, Maccarrone
M
, Fezza
F
, Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases
. J Neurosci
. 2003
;23
(10
):4127
–33
. .12.
Amar
MB
. Cannabinoids in medicine: a review of their therapeutic potential
. J Ethnopharmacol
. 2006
;105
(1–2
):1
–25
.13.
Mechoulam
R
, Shani
A
, Edery
H
, Grunfeld
Y
. Chemical basis of hashish activity
. Science
. 1970
;169
(3945
):611
–2
. .14.
Iuvone
T
, Esposito
G
, De Filippis
D
, Scuderi
C
, Steardo
L
. Cannabidiol: a promising drug for neurodegenerative disorders?
CNS Neurosci Ther
. 2009
;15
(1
):65
–75
. .15.
Esposito
G
, Scuderi
C
, Savani
C
, Steardo
L
Jr, De Filippis
D
, Cottone
P
, Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression
. Br J Pharmacol
. 2007
;151
(8
):1272
–9
. .16.
Pacher
P
, Bátkai
S
, Kunos
G
. The endocannabinoid system as an emerging target of pharmacotherapy
. Pharmacol Rev
. 2006
;58
(3
):389
–462
. .17.
Brown
AJ
. Novel cannabinoid receptors
. Br J Pharmacol
. 2007
;152
(5
):567
–75
. .18.
Ruhl
T
, Karthaus
N
, Kim
BS
, Beier
JP
. The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs
. Exp Cell Res
. 2020
;389
:111881
. .19.
Mackie
K
. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength
. Int J Obes
. 2006
;30 Suppl 1
(1
):S19
–23
. .20.
Spiller
KJ
, Bi
GH
, He
Y
, Galaj
E
, Gardner
EL
, Xi
ZX
. Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats
. Br J Pharmacol
. 2019
;176
(9
):1268
–81
. .21.
Yu
S
, Xu
X
, Feng
J
, Liu
M
, Hu
K
. Chitosan and chitosan coating nanoparticles for the treatment of brain disease
. Int J Pharm
. 2019
;560
:282
–93
. .22.
Ojeda-Hernández
DD
, Canales-Aguirre
AA
, Matias-Guiu
J
, Gomez-Pinedo
U
, Mateos-Díaz
JC
. Potential of chitosan and its derivatives for biomedical applications in the central nervous system
. Front Bioeng Biotechnol
. 2020
;8
:389
. .23.
Elieh-Ali-Komi
D
, Hamblin
MR
. Chitin and chitosan: production and application of versatile biomedical nanomaterials
. Int J Adv Res
. 2016
;4
(3
):411
.24.
Hajipour
S
, Sarkaki
A
, Farbood
Y
, Eidi
A
, Mortazavi
P
, Valizadeh
Z
. Effect of gallic acid on dementia type of alzheimer disease in rats: electrophysiological and histological studies
. Basic Clin Neurosci
. 2016
;7
(2
):97
. .25.
El-Denshary
ES
, Aljawish
A
, El-Nekeety
AA
, Hassan
NS
, Saleh
RH
, Rihn
BH
, Possible synergistic effect and antioxidant properties of chitosan nanoparticles and quercetin against carbon tetrachloride-induce hepatotoxicity in rats
. Soft Nanosci Lett
. 2015
;5
:36
–51
.26.
Deiana
S
, Watanabe
A
, Yamasaki
Y
, Amada
N
, Arthur
M
, Fleming
S
, Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive: compulsive behaviour
. Psychopharmacology
. 2012
;219
(3
):859
–73
.27.
Wen
P
, Luo
H
, Zhou
L
, Song
Z
, Li
W
, Zhou
J
. Effects of tanshinone IIA on the expressions of caspase-3, Akt and NF-κB in the brains of rat models of alzheimerʼs disease
. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
. 2014
;30
(2
):155
–9
.28.
Paxinos
G
, Watson
C
. The rat brain in stereotaxic coordinates: hard cover edition
. Elsevier
; 2006
.29.
Chandirika
JU
, Sindhu
R
, Selvakumar
S
, Annadurai
G
. Herbal extract encapsulated in chitosan nanoparticle: a novel strategy for the treatment of urolithiasis
. Indo Am J Pharm Sci
. 2018
;5
(3
):1955
–61
.30.
Mason
TG
, Wilking
JN
, Meleson
K
, Chang
CB
, Graves
SM
. Nanoemulsions: formation, structure, and physical properties
. J Phys Condens Matter
. 2006
;18
(41
):R635
. .31.
Wang
H
, Wang
H
, Cheng
H
, Che
Z
. Ameliorating effect of luteolin on memory impairment in an alzheimerʼs disease model
. Mol Med Rep
. 2016
;13
(5
):4215
–20
. .32.
Powers
MM
, Clark
G
. An evaluation of cresyl echt violet acetate as a Nissl stain
. Stain Technol
. 1955
;30
(2
):83
–8
. .33.
Guan
R
, Lv
J
, Xiao
F
, Tu
Y
, Xie
Y
, Li
L
. Potential role of the cAMP/PKA/CREB signalling pathway in hypoxic preconditioning and effect on propofol: induced neurotoxicity in the hippocampus of neonatal rats
. Mol Med Rep
. 2019
;20
(2
):1837
–45
. .34.
Kocahan
S
, Doğan
Z
. Mechanisms of alzheimer’s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors
. Clin Psychopharmacol Neurosci
. 2017
;15
(1
):1
.35.
Hashimoto
T
, Adams
KW
, Fan
Z
, McLean
PJ
, Hyman
BT
. Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay
. J Biol Chem
. 2011
;286
(31
):27081
–91
. .36.
Esposito
G
, Scuderi
C
, Valenza
M
, Togna
G
, Latina
V
, De Filippis
D
, Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal and promotes hippocampal neurogenesis through PPARγ involvement
. PLoS One
. 2011
;6
(12
):e28668
.37.
Prins
ND
, Visser
PJ
, Scheltens
P
. Can novel therapeutics halt the amyloid cascade?
Alzheimers Res Ther
. 2010
;2
(2
):5
–3
. .38.
Iuvone
T
, Esposito
G
, Esposito
R
, Santamaria
R
, Di Rosa
M
, Izzo
AA
. Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
. J Neurochem
. 2004
;89
(1
):134
–41
. .39.
Varan
C
, Bilensoy
E
. Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment
. Beilstein J Nanotechnol
. 2017
;8
(1
):1446
–56
. .40.
Tzeyung
AS
, Shadab
Md
, Madheswaran
T
, Alhakamy
NA
, Aldawsari
HM
, Fabrication, optimization, and evaluation of rotigotine-loaded chitosan nanoparticles for nose-to-brain delivery
. Pharmaceutics
. 2019
;11
(1
):26
. .41.
Nagpal
K
, Singh
SK
, Mishra
DN
. Optimization of brain targeted chitosan nanoparticles of rivastigmine for improved efficacy and safety
. Int J Biol Macromol
. 2013
;59
:72
–83
. .42.
Ferreira
FF
, Ribeiro
FF
, Rodrigues
RS
, Sebastião
AM
, Xapelli
S
. Brain-derived neurotrophic factor (BDNF) role in cannabinoid-mediated neurogenesis
. Front Cell Neurosci
. 2018
;12
:441
. .43.
Talarico
G
, Trebbastoni
A
, Bruno
G
, de Lena
C
. Modulation of the cannabinoid system: a new perspective for the treatment of the alzheimer’s disease
. Curr Neuropharmacol
. 2019
;17
(2
):176
–83
.44.
45.
Benito
C
, Tolón
RM
, Pazos
MR
, Núñez
E
, Castillo
AI
, Romero
J
. Cannabinoid CB2 receptors in human brain inflammation
. Br J Pharmacol
. 2008
;153
(2
):277
–85
. .46.
Martín-Moreno
AM
, Reigada
D
, Ramírez
BG
, Mechoulam
R
, Innamorato
N
, Cuadrado
A
, Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to alzheimerʼs disease
. Mol Pharmacol
. 2011
;79
(6
):964
–73
. .47.
Ouyang
QQ
, Zhao
S
, Li
SD
, Song
C
. Application of chitosan, chitooligosaccharide, and their derivatives in the treatment of alzheimerʼs disease
. Mar Drugs
. 2017
;15
(11
):322
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
